CRISPR Therapeutics AG (CRSP) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Zug, Switzerland. Le PDG actuel est Samarth Kulkarni.
CRSP a date d'introduction en bourse 2016-10-19, 393 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $5.46B.
CRISPR Therapeutics AG is a gene editing company headquartered in Zug, Switzerland, that develops gene-based medicines using its proprietary CRISPR/Cas9 technology platform, which enables precise modifications to genomic DNA. The company's clinical pipeline spans multiple therapeutic areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases, with lead programs such as CTX001 for beta-thalassemia and sickle cell disease, CTX110 and CTX120 for various cancers, and VCTX210 for type 1 diabetes. CRISPR also pursues in vivo gene-editing programs targeting liver, lung, muscle, and central nervous system diseases. The company has established strategic partnerships with major pharmaceutical and biotechnology firms including Bayer, Vertex Pharmaceuticals, ViaCyte, Nkarta, and Capsida Biotherapeutics to advance its therapeutic development efforts.
